Now 100% Sensitive at Detecting CXCR4 HIV-1 Levels as Low as 0.3%
SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc. (Nasdaq: MGRM) today announced immediate availability of
enhanced sensitivity in its Trofile assay. Trofile was introduced
commercially upon FDA approval of Selzentry(TM) (maraviroc), Pfizer's first
in class CCR5 antagonist, in August 2007. Optimization of Monogram's
Trofile(TM) HIV co-receptor tropism assay has made it substantially more
sensitive at identifying very low levels of CXCR4 using virus (X4 or
dual/mixed tropic) in HIV-1 patient samples while maintaining a high degree
of accuracy. The assay can now detect X4 virus present at levels less than
0.3% of the total virus population, and at that level of X4 virus, the
assay is 100% sensitive. This improvement in sensitivity should give
physicians a greater level of confidence that the Trofile assay is
selecting the most appropriate patients for CCR5 antagonist therapy.
Tropism refers to the chemokine co-receptor on the surface of CD4+
cells that a particular variant of HIV uses to enter the cell. "R5"
variants use the CCR5 co-receptor, "X4" viruses use the CXCR4 co-receptor,
and dual/mixed HIV uses both co-receptors. New CCR5 antagonist therapies,
such as Pfizer's Selzentry block the "R5" variants of HIV from entering
through the CCR5 co-receptor. CCR5 antagonists have not been shown to be
effective against X4 or dual/mixed variants.
Trofile is now 100% sensitive at detecting CXCR4 minor variants as low
as 0.3%, a sensitivity increase of 30-fold on average. Monogram says that
with this increase in sensitivity, the assay remains highly accurate.
"Pfizer welcomes advances and innovation in tropism detection, such as
the enhanced sensitivity of Trofile, which will give physicians important
information when deciding whether or not to incorporate a CCR5 antagonist
like Selzentry into a patient's treatment regimen," said Dr. Howard Mayer,
MD, Executive Director, Pfizer Development Team Leader for HIV/AIDS. Pfizer
and Monogram have a collaboration agreement for commercialization of
Trofile outside of the U.S.
"Detection of CXCR4-using minority variants has been shown as an
important indicator of CCR5 antagonist treatment success and Trofile is the
only clinically validated assay to identify co-receptor tropism, a step the
FDA and EMEA has determined is critical in selecting patients for treatment
with a CCR5 antagonist," said Monogram CEO William Young. "Trofile is the
gold standard in tropism testing and the enhanced sensitivity version now
available sets a new standard for performance so that the thousands of
physicians who rely on our assay can better direct patient selection."
Trofile examines the complete gp160 coding region of the HIV-1 envelope
protein, ensuring that all of the determinants of tropism are tested. In a
retrospective analysis reported at the recent Conference on Retroviruses
and Opportunistic Infections, the enhanced assay improved patient selection
by identifying more cases of dual / mixed virus, and more accurately
predicted virologic outcomes. In addition to providing patient selection
for Selzentry's pivotal trials, Trofile has been used for patient selection
and monitoring in all Phase II and III clinical trials of co-receptor
antagonists.
About Trofile
Trofile is a clinically validated patient selection tropism assay that
determines whether a patient is infected with a strain of HIV that uses
either the CCR5 co-receptor, the CXCR4 co-receptor, or a combination of
CCR5 and CXCR4 to enter cells. The use of CCR5, CXCR4 or both co-receptors
defines the "tropism" of the virus strain. Trofile amplifies the envelope
gene from a patient's HIV genome (from their blood sample) and then uses it
to make HIV particles containing the patient's virus envelope protein. The
resultant HIV particles are then used to infect cells that contain the CCR5
co-receptor or the CXCR4 co-receptor on the cell surface. Once the virus
infects the cell, it undergoes a single round of replication. Virus
replication results in the production of luciferase from a luciferase gene
that is carried into the cell by the virus. The production of luciferase in
either CCR5 cells, CXCR4 cells or both cell types defines the co-receptor
tropism of the patient virus. Trofile is the only clinically validated
tropism assay and has been used to select patients in all phase II and
phase III studies of CCR5 antagonists to date.
About Monogram
Monogram is a biotechnology company advancing individualized medicine
by discovering, developing and marketing innovative products to guide and
improve treatment of serious infectious diseases and cancer. The Company's
products are designed to help doctors optimize treatment regimens for their
patients that lead to better outcomes and reduced costs. The Company's
technology is also being used by numerous biopharmaceutical companies to
develop new and improved antiviral therapeutics and vaccines as well as
targeted cancer therapeutics. More information about the Company and its
technology can be found on its web site at http://www.monogrambio.com
Forward Looking Statements
Certain statements in this press release are forward-looking. These
forward-looking statements include references to the demand for our Trofile
Assay, the potential use of our Trofile Assay for patient selection for
Selzentry, the size and timing of clinical trials utilizing our products,
the outlook for Selzentry and our Trofile Assay, the number of patients
each year in the U.S. who potentially could be candidates for new classes
of HIV drugs such as Selzentry, expected protection provided by patents,
possible regulation of Trofile and our other products by the FDA, and
activities expected to occur in connection with the Pfizer collaboration.
These forward-looking statements are subject to risks and uncertainties and
other factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not limited to:
the risk that physicians may not use a molecular diagnostic for patient
selection for Selzentry or other HIV drugs; risks related to the
implementation of the collaboration with Pfizer; risks related to our
ability to recognize revenue from activities under the collaboration with
Pfizer; risks and uncertainties relating to the performance of our
products; the growth in revenues; the size, timing and success or failure
of any clinical trials for CCR5 inhibitors, entry inhibitors or integrase
inhibitors; the risk that our Trofile Assay may not be utilized for patient
use with Selzentry and other CCR5 inhibitors; our ability to successfully
conduct clinical studies and the results obtained from those studies;
whether larger confirmatory clinical studies will confirm the results of
initial studies; our ability to establish reliable, high-volume operations
at commercially reasonable costs; expected reliance on a few customers for
the majority of our revenues; the annual renewal of certain customer
agreements; actual market acceptance of our products and adoption of our
technological approach and products by pharmaceutical and biotechnology
companies; our estimate of the size of our markets; our estimates of the
levels of demand for our products; the impact of competition; the timing
and ultimate size of pharmaceutical company clinical trials; whether payers
will authorize reimbursement for our products and services and the amount
of such reimbursement that may be allowed; whether the FDA or any other
agency will decide to further regulate our products or services, including
Trofile; whether the draft guidance on Multivariate Index Assays issued by
FDA will be subsequently determined to apply to our current or planned
products; whether we will encounter problems or delays in automating our
processes; the ultimate validity and enforceability of our patent
applications and patents; the possible infringement of the intellectual
property of others; whether licenses to third party technology will be
available; whether we are able to build brand loyalty and expand revenues;
restrictions on the conduct of our business imposed by the Pfizer, Merrill
Lynch and other debt agreements; the impact of additional dilution if our
convertible debt is converted to equity; and whether we will be able to
raise sufficient capital in the future, if required. For a discussion of
other factors that may cause actual events to differ from those projected,
please refer to our most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as other subsequent filings with the
Securities and Exchange Commission. We do not undertake, and specifically
disclaim any obligation, to revise any forward-looking statements to
reflect the occurrence of anticipated or unanticipated events or
circumstances after the date of such statements.
Trofile is a trademark of Monogram Biosciences, Inc. Selzentry is a
trademark of Pfizer Inc.
contacts: Alfred G. Merriweather Jeremiah Hall
Chief Financial Officer Feinstein Kean Healthcare
Tel: 650 624 4576 Tel: 415 677 2700
amerriweather@ jeremiah.hall@
monogrambio.com fkhealth.com
SOURCE Monogram Biosciences, Inc.
 back to top
Related links:
http://www.monogrambio.com
CONTACT:
Alfred G. Merriweather, Chief Financial
Officer of Monogram Biosciences, Inc., +1-650-624 4576,
amerriweather@monogrambio.com; or Jeremiah Hall of Feinstein Kean
Healthcare, +1-415-677-2700, jeremiah.hall@fkhealth.com
|
